NanO2 may assist in mitigating secondary cellular brain damage after traumatic brain injury.

The design for an efficient Phase IIb clinical trial in stroke to test DDFPe in patients with Large Vessel Occlusions.

Although small, this trial shows that DDFPe used as a radiosensitizer appears to be safe and may provide some survival benefit.

This randomized, placebo-controlled, double-blind, dose-escalation clinical trial in acute ischemic stroke patients was designed to...

DDFPe treatment in rats with myocardial infarction was associated by significantly reduced ischemia-reperfusion injury.

Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...

DDFPe efficiently offloads oxygen to hypoxic environments. Link to publication

Animal studies, for both hemorrhagic shock and TBI, show promising effects of DDFPe as a resuscitation fluid.

In this swine model of TBI, administration of DDFPe resulted in lower injury scores for spongiosis and ischemic neurons.

DDFPe reduces infarct volume and neurological function following anterior ischemic stroke.

MRI scans indicated that oxygen breathing with DDFPe administration improved tumor oxygenation.

DDFPe increased brain tissue oxygen tension following TBI in rats and should be evaluated further as a possible treatment for TBI.

DDFPe results in a significant increase in intra-tumoral oxygen tension for up to 45 minutes in our pancreatic xenograft model in mice.

Intravenous injection of DDFPe in mice with tumors increases tumor oxygen levels.

DDFPe significantly extends the time window for tPA therapy.

DDFPe delays and reduces MRI markers of stroke in the early hours following vascular occlusion in a rat stroke model.

Increasing the number of DDFPe applications was significant in reducing the incidence of premature death.

DDFPe alleviates hypoxia in areas of ischemia.

DDFPe administration in mice with pancreatic tumor xenografts resulted in increased tumor oxygen tension lasting up to two hours.

DDFPe treatment provides significant neuroprotection when assessed six hours post stroke.